Article
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Nature communications - 9 Jan 2017
Taylor Renea A, Fraser Michael, Livingstone Julie, Espiritu Shadrielle Melijah G, Thorne Heather, Huang Vincent, Lo Winnie, Shiah Yu-Jia, Yamaguchi Takafumi N, Sliwinski Ania, Horsburgh Sheri, Meng Alice, Heisler Lawrence E, Yu Nancy, Yousif Fouad, Papargiris Melissa, Lawrence Mitchell G, Timms Lee, Murphy Declan G, Frydenberg Mark, Hopkins Julia F, Bolton Damien, Clouston David, McPherson John D, van der Kwast Theodorus, Boutros Paul C, Risbridger Gail P, Bristow Robert G
Abstract excerpt
Germline mutations in the BRCA2 tumour suppressor are associated with both an increased lifetime risk of developing prostate cancer (PCa) and increased risk of aggressive disease. To understand this aggression, here we profile the genomes and methylomes of localized PCa from 14 carriers of deleterious germline BRCA2 mutations (BRCA2-mutant PCa). We show that BRCA2-mutant PCa harbour increased genomic instability...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.